Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab for Recurrent CDI in IBD Patients
NCT04626947Phase 4Terminated
- Sponsor
- David Binion
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bezlotoxumab in Clostridium difficile infection (CDI), sponsored by David Binion. Primary endpoints: Number of Participants With Recurrent C. Diff Infection at 90 Days, Number of Participants With Recurrent C. Diff Infection at 12 Months and 1 more. Started Oct 2021; status: terminated.
02
Drugs
bezlotoxumab
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04626947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626947.